KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization Amortization Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Repurchased Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Non-Current Receivables Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In Process Receivables - Net Receivables - Other Receivables Refunds Shares Outstanding Shares Outstanding Shares Repurchased Short-Term Debt repayments

Novartis Ag (NVS) Shares Repurchased (2017 - 2025)

Novartis Ag's Shares Repurchased history spans 7 years, with the latest figure at -$2.7 billion for Q2 2025.

On a quarterly basis, Shares Repurchased fell 67.95% to -$2.7 billion in Q2 2025 year-over-year; TTM through Jun 2025 was -$12.9 billion, a 17.76% increase, with the full-year FY2019 number at -$3.0 million, up 98.8% from a year prior.
Shares Repurchased hit -$2.7 billion in Q2 2025 for Novartis Ag, roughly flat from -$2.7 billion in the prior quarter.
Over the last five years, Shares Repurchased for NVS hit a ceiling of -$1.6 billion in Q2 2024 and a floor of -$5.8 billion in Q4 2023.
Historically, Shares Repurchased has averaged -$3.4 billion across 4 years, with a median of -$2.7 billion in 2024.
Biggest five-year swings in Shares Repurchased: surged 53.53% in 2024 and later tumbled 67.95% in 2025.
Tracing NVS's Shares Repurchased over 4 years: stood at -$5.3 billion in 2022, then dropped by 11.17% to -$5.8 billion in 2023, then surged by 53.53% to -$2.7 billion in 2024, then increased by 0.04% to -$2.7 billion in 2025.
Business Quant data shows Shares Repurchased for NVS at -$2.7 billion in Q2 2025, -$2.7 billion in Q4 2024, and -$1.6 billion in Q2 2024.